文献速递老年慢病共病管理衰弱、肌少症与跌倒

美国长期护理机构≥60岁成人接种佐剂RSVPreF3疫苗的公共卫生影响

Public Health Impact of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged ≥60 Years Residing in Long-Term Care Settings.
PubMed 文献 · J Am Med Dir Assoc · 2026-10-19

该研究用静态多队列马尔可夫模型模拟美国长期护理机构≥60岁成人接种佐剂RSVPreF3疫苗与不接种相比5年内的公共卫生影响。模拟的2,113,600人中378,656人接种1剂,结果减少33,989例RSV病例、11,634例住院和1,355例死亡,避免1例RSV下呼吸道疾病需接种14人。结论认为该疫苗可避免大量不良健康结局。

要点

  • 模拟5年减少33,989例RSV病例,其中下呼吸道疾病26,302例。
  • 减少19,639次门诊、1,556次急诊和11,634例住院。
  • 避免1例RSV下呼吸道疾病需接种人数(NNV)为14人。

核心结论

  • 美国长期护理机构≥60岁成人接种佐剂RSVPreF3疫苗可避免大量RSV相关不良健康结局,支持其作为预防策略。

研究设计与样本

  • 采用静态多队列马尔可夫模型的公共卫生影响分析。
  • 模拟美国长期护理机构≥60岁成人接种佐剂RSVPreF3疫苗与不接种比较,时间跨度5年,使用真实世界RSV疫苗接种率数据。

主要发现

  • 模拟的2,113,600人中378,656人接种1剂佐剂RSVPreF3疫苗。
  • 接种后减少33,989例RSV病例,包括7,688例上呼吸道疾病和26,302例下呼吸道疾病(RSV-LRTD)。
  • 减少19,639次门诊就诊、1,556次急诊就诊和11,634例住院。
  • 5年内RSV相关死亡减少1,355例,折扣生命年和质量调整生命年损失分别减少7,221和6,043。
  • 避免1例RSV-LRTD的估计NNV为14人。

关键数值与推荐

  • 避免1例RSV-LRTD的NNV为14人。
  • 5年模拟减少RSV相关死亡1,355例。

临床怎么用

  • 长期护理机构≥60岁成人接种佐剂RSVPreF3疫苗可减少RSV相关就诊、住院和死亡。
  • 未来需确保长期护理机构居民能够获得RSV疫苗接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Adults aged ≥60 years and adults with certain health conditions are at increased risk for severe respiratory syncytial virus (RSV) disease, which can have a substantial clinical burden. Residents in long-term care settings often have multiple risk factors, including age ≥60 years, underlying health conditions, and/or frailty, compounding risk for severe RSV disease. This study evaluated the public health impact of adjuvanted RSV prefusion F3 (RSVPreF3) vaccination on averted RSV disease burden. DESIGN: Public health impact analysis using a static, multicohort Markov model. SETTING AND PARTICIPANTS: United States (US) adults aged ≥60 years residing in long-term care settings. METHODS: Adjuvanted RSVPreF3 vaccination vs no vaccination was simulated over 5 years using real-world RSV vaccination uptake data. Other model inputs have been previously validated and reported. This analysis estimated avoided RSV-related health outcomes due to vaccination, as well as the number needed to vaccinate (NNV) to avoid RSV-related outcomes. RESULTS: Among the modeled 2,113,600 US adults aged ≥60 years residing in long-term care settings, 378,656 were simulated to receive 1 dose of adjuvanted RSVPreF3. RSV vaccination resulted in 33,989 fewer RSV cases, including 7688 fewer RSV-upper respiratory tract disease cases and 26,302 fewer RSV-lower respiratory tract disease cases (RSV-LRTD). Avoided healthcare resource use included 19,639 fewer outpatient visits, 1556 fewer emergency department visits, and 11,634 fewer hospitalizations. RSV-related deaths declined by 1355 over 5 years, alongside 7221 and 6043 fewer discounted life years and quality-adjusted life years lost, respectively. To avoid 1 RSV-LRTD case, the estimated NNV was 14 individuals. CONCLUSIONS AND IMPLICATIONS: Adjuvanted RSVPreF3 vaccination avoided a substantial number of negative health outcomes among US adults aged ≥60 years residing in long-term care settings, providing evidence of its impact as a prevention strategy. Future efforts are needed to ensure that long-term care residents have access to RSV vaccination.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. La EM, Graham J, Grace M, et al. Public Health Impact of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged ≥60 Years Residing in Long-Term Care Settings. J Am Med Dir Assoc. 2026. PMID: 42896317. doi:10.1016/j.jamda.2026.106406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。